Table of contents

ORIGINAL ARTICLE

• Mortality predictions for Ireland, 2001–2015: cancers of the breast, ovary, and cervix and corpus uteri (1 January, 2006)

  P. O'LORCAIN, H. Comber
• Improved short-term survival for advanced ovarian, tubal, and peritoneal cancer patients operated at teaching hospitals (1 January, 2006)

  T. Paulsen, K. Kjærheim, J. KÆRN, S. Tretli, C. Tropé
• Stage- and CA125–related survival in patients with epithelial ovarian cancer treated at a cancer center (1 January, 2006)

  R. E. Board, C. T.P.H. Bruijns, A. E. Pronk, W. D.J. Ryder, P. M. Wilkinson, R. Welch, J. H. Shanks, G. Connolly, R. J. Slade, K. Reynolds, H. C. Kitchener, G. C. Jayson
• Stage III and IV ovarian cancer in the South West of England: five-year outcome analysis for cases treated in 1998 (1 January, 2006)

  J. Bailey, J. Murdoch, R. Anderson, J. Weeks, C. Foy
• Risk of malignancy index for referral of ovarian cancer cases to a tertiary center: does it identify the correct cases? (1 January, 2006)

  J. Bailey, A. Tailor, R. Naik, A. Lopes, K. Godfrey, H. M. Hatem, J. Monaghan
• Role of laparoscopy to evaluate candidates for complete cytoreduction in advanced stages of epithelial ovarian cancer (1 January, 2006)

  X. Deffieux, D. Castaigne, C. Pomel
• “True” versus “apparent” stage I epithelial ovarian cancer: value of frozen section analysis (1 January, 2006)

  R. Naik, P. Cross, A. Lopes, K. Godfrey, M. H. Hatem
• A retrospective analysis of neoadjuvant platinum-based chemotherapy versus up-front surgery in advanced ovarian cancer (1 January, 2006)

  H. Steed, A. M. Oza, J. Murphy, S. Laframboise, G. Lockwood, D. De Petrillo, J. Sturgeon, B. Rosen
• Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study (1 January, 2006)

  K. N. Gaarenstroom, B. Van Der Hiel, R. A.E.M. Tollenaar, G. R. Vink, F. W. Jansen, C. J. Van Asperen, G. G. Kenter
• Gemcitabine–carboplatin–paclitaxel combination as first-line therapy in advanced ovarian carcinoma: a single institution phase II study in 24 patients (1 January, 2006)

  L. Fuso, F. Amant, P. Neven, P. Berteloot, I. Vergote
• Topotecan and liposomal doxorubicin in recurrent ovarian cancer: is sequence important? (1 January, 2006)

  J. Dupont, C. Aghajanian, G. Andrea, M. Lovegren, S. Chuai, E. Venkatraman, M. Hensley, S. Anderson, D. Spriggs, P. Sabbatini
• Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study (1 January, 2006)

  G. Bolis, S. Danese, S. Tateo, E. Rabaiotti, G. D'Agostino, C. Merisio, G. Scarfone, G. Polverino, F. Parazzini
• A phase II study of pegylated liposomal doxorubicin oxaliplatin and cyclophosphamide as second-line treatment in relapsed ovarian carcinoma (1 January, 2006)

  M. R. Valerio, P. Tagliaferri, F. Raspagliesi, F. Fulfaro, G. Badalamenti, C. Arcara, G. Cicero, A. Russo, S. Venuta, G. Guarneri, N. Gebbia
• Screening for familial ovarian cancer—management and outcome of women with moderate to high risk of developing ovarian cancer (1 January, 2006)

  G. C. Rieck, K. Lim, M. T. Rogers, E. France, J. R. Gray, N. Amso, A. S. Evans, R. H. Howells, A. N. Fiander
• Estimation of probability of malignancy using a logistic model combining color Doppler ultrasonography, serum CA125 level in women with a pelvic mass (1 January, 2006)

  A. S. Mousavi, S. Borna, S. Moeinoddini
• Whole-body positron emission tomography and tumor marker CA125 for detection of recurrence in epithelial ovarian cancer (1 January, 2006)

  M. Murakami, T. Miyamoto, T. Iida, H. Tsukada, M. Watanabe, M. Shida, H. Maeda, S. Nasu, S. Yasuda, M. Yasuda, M. Ide
• Image-guided biopsy in women with breast cancer presenting with peritoneal carcinomatosis (1 January, 2006)

  M. J. Hewitt, G. D. Hall, N. Wilkinson, T. J. Perren, G. Lane, J. A. Spencer
• Magnetic resonance imaging–based prospective detection of intraperitoneal human ovarian carcinoma xenografts treatment response (1 January, 2006)

  J. Klostergaard, E. Auzenne, S. Ghosh, D. Farquhar, B. Rivera, R. E. Price
• Primary gynecological neoplasms and clinical outcomes in patients diagnosed with breast carcinoma (1 January, 2006)

  P. F. Escobar, R. Patrick, L. Rybicki, N. Al-Husaini, C. M. Michener, J. P. Crowe
• Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period (1 January, 2006)

  K. S. Jaaback, L. Ludeman, N. L. Clayton, L. Hirschowitz
• Primary psammocarcinoma of the peritoneum (1 January, 2006)

  T. BİLGİN, S. ÖZUYSAL, H. Cankiliç
• Metastatic tumors to the ovaries: a study of 170 cases in northern Thailand (1 January, 2006)

  S. Khunamornpong, P. Suprasert, W. Na Chiangmai, S. Siriaunkgul
• Plasma proteomic pattern as biomarkers for ovarian cancer (1 January, 2006)

  Y.-W Lin, C.-Y Lin, H.-C Lai, J.-Y Chiou, C.-C Chang, M.-H Yu, T.-Y Chu
• Predicting the clinical behavior of ovarian cancer from gene expression profiles (1 January, 2006)

  F. De Smet, N. L.M.M. Pochet, K. Engelen, T. Van Gorp, P. Van Hummelen, K. Marchal, F. Amant, D. Timmerman, B. L.R. De Moor, I. B. Vergote
• Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy (1 January, 2006)

  A. P.G. Crijns, E. W. Duiker, S. De Jong, P. H.B. Willemse, A. G.J. Van Der Zee, E. G.E. De Vries
• BRCA1 expression in a large series of sporadic ovarian carcinomas: a Gynecologic Oncology Group study (1 January, 2006)

  M. Thrall, H. H. Gallion, R. Kryscio, M. Kapali, D. K. Armstrong, Julie A. Deloia
• BRCA1 germline mutations in Chinese patients with hereditary breast and ovarian cancer (1 January, 2006)

  N. Li, X. Zhang, Y. Cai, X. Xu, L. Zhang, K.-F. Pan, L.-Y Wu, M.-R Wang
• Fas gene promoter –670 polymorphism in gynecological cancer (1 January, 2006)

  M. Ueda, Y. Terai, K. Kanda, M. Kanemura, M. Takehara, H. Yamaguchi, K. Nishiyama, M. Yasuda, M. Ueki
• Prognostic significance of vascular endothelial growth factor expression in ovarian cancer patients: a long-term follow-up (1 January, 2006)

  C. Rudlowski, A.-K. Pickart, C. Fuhljahn, T. Friepoertner, B. Schlehe, S. Biesterfeld, W. Schroeder
• CAG repeat length in exon 1 of the androgen receptor gene is related to age of diagnosis but not germ line BRCA1 mutation status in ovarian cancer (1 January, 2006)

  S. C. Kim, W. Ju, V. Mahavni, J. P. Geisler, R. E. Buller
• Methylation of death-associated protein kinase in ovarian carcinomas (1 January, 2006)

  Y. Collins, R. Dicioccio, B. Keitz, S. Lele, K. Odunsi
• Ras antagonist inhibits growth and chemosensitizes human epithelial ovarian cancer cells (1 January, 2006)

  M. E. Beiner, H. Niv, R. Haklai, G. Elad-Sfadia, Y. Kloog, G. Ben-Baruch
• Atypical reactive ovarian surface epithelium, a pitfall in pathologic assessment (1 January, 2006)

  N. E. Aydin, Ö. ÇELIK, Ş. Hasçalik, M. N. Edali
• Active and passive smoking and risk of ovarian cancer (1 January, 2006)

  J. A. Baker, O. O. Odunuga, K J. Rodabaugh, M E. Reid, R J. Menezes, K B. Moysich
• Complementary and alternative medicine use in patients with gynecological cancers in Europe (1 January, 2006)

  A. Molassiotis, M. Browall, L. Milovics, V. Panteli, E. Patiraki, P. Fernandez-Ortega
• Good fetal outcome of pregnancies with gynecologic cancer conditions: cases and literature review (1 January, 2006)

  F. Ghaemmaghami, M. Hasanzadeh
• Pulmonary papillary serous adenocarcinoma with intraperitoneal and ovarian tumors: identification of primary site. A case report (1 January, 2006)

  M. Y. Chen, S. M. Jung, K. K. Ng, T. C. Chang
• Secondary leukemia after treatment with paclitaxel and carboplatin in a patient with recurrent ovarian cancer (1 January, 2006)

  H. T. See, D. A. Thomas, C. Bueso-Ramos, J. Kavanagh
• Clinicopathologic study of vascular endothelial growth factor, thrombospondin-1, and microvessel density assessed by CD34 in patients with stage III ovarian carcinoma (1 January, 2006)

  V. Karavasilis, V. Malamou-Mitsi, E. Briasoulis, E. Tsanou, E. Kitsou, N. Pavlidis
• Expression of cyclooxygenase-2 in epithelial ovarian tumors and its relation to vascular endothelial growth factor and p53 expression (1 January, 2006)

  J. S. Lee, Y. D. Choi, J. H. Lee, J. H. Nam, C. Choi, M. C. Lee, C. S. Park, S. W. Juhng, K. W. Min
• PTEN and p53 expression in primary ovarian carcinomas: immunohistochemical study and discussion of pathogenetic mechanisms (1 January, 2006)

  C. P. Gomes, L. A.L.A. Andrade
• Microsatellite instability in mitochondrial genome of common female cancers (1 January, 2006)

  Y. Wang, V. W.S. Liu, P. C.K. Tsang, P. M. Chiu, A. N.Y. Cheung, U. S. Khoo, P. Nagley, H. Y.S. Ngan
• Treatment of uterine papillary serous carcinoma with platinum-based chemotherapy and paclitaxel (1 January, 2006)

  A. P. Vaidya, R. Littell, C. Krasner, L. R. Duska
• Is there a role for neoadjuvant chemotherapy in the treatment of stage IV serous endometrial carcinoma? (1 January, 2006)

  E. Despierre, P. Moerman, I. Vergote, F. Amant
• Uterine papillary serous carcinoma: evaluation of multimodality treatment with abdominopelvic radiotherapy and chemotherapy (1 January, 2006)

  H. Steed, L. Manchul, B. Rosen, A. Fyles, G. Lockwood, S. Laframboise, J. Murphy, M. Milosevic, W. Chapman, A M. Oza
• Immunohistochemical characterization of endocervical papillary serous carcinoma (1 January, 2006)

  S. Nofech-Mozes, G. Rasty, N. Ismiil, A. Covens, M. A. Khalifa